Elucid
Elucid Bioimaging is a medical technology company leveraging machine intelligence to improve the accuracy, experience, and cost-effectiveness of vascular diagnostic imaging.
Elucid – WhatisWhatis. Publications. Can machine learning and artificial intelligence save lives? As we move forward with the technology like artificial intelligence and machine learning, we can only access its true power for good through the skills of talented programmers, working in cooperation with medical professionals.
Boston, Massachusetts - Feb 17, 2020 - A leading software company called Elucid Bioimaging believes it can. Approximately 1.5 million Americans have a heart attack or stroke each year. They are the two leading causes of death in developed countries around the world, but do we have an opportunity to improve our ability to predict these events? And can we deliver personalized treatment to prevent them? Boston-based Elucid Bioimaging says they can… and have the numbers to prove it. To understand how this works, it is important to recognize how heart attacks and strokes occur. Elucid Bioimaging realized this issue and spent 10+ years researching & developing a solution. An important benefit of vascuCAP is the cost savings experienced by health systems and patients. Unveiling an AI-driven risk stratification tool to attain better stroke prediction.
But in order to get to the heart of Lal’s current risk prediction quest, he first takes Vascular Connections on a little history tour of carotid disease.
Those studies to which he draws reference—beginning in the 1970s and continuing unabated through today— were united in their search for the best treatment for asymptomatic carotid stenosis patients. And all of them indicate that “if you take 100 people with asymptomatic carotid stenosis and perform carotid endarterectomy [CEA], and randomize 100 people with asymptomatic carotid disease and give them the best available medical therapy,” the patients who received a CEA did a little better, Lal says. Yet, the challenge remains that, even among those who did not undergo surgery, stroke rates were “not tremendously high.” If those 100 patients are followed, about two per year suffer a stroke. The bottom line: Percentage stenosis is not the ideal way to risk stratify patients in order to identify those who will have a stroke. About Elucid.
Elucid Biotechnology - COVID-19 - USA, Other Countries - Free Classifieds Ads. Elucid - 4shared user page - 0 downloads. Biologic therapy for psoriasis may reduce heart disease, reveals study. Dallas: Patients with psoriasis treated with biologic therapy, which are protein-based infusions to suppress inflammation, had a significant reduction in high-risk plaque in heart arteries, over one-year, according to new research.
The research was published in Circulation: Cardiovascular Imaging, an American Heart Association journal. Chronic inflammation in people with psoriasis is associated with a higher risk of developing coronary artery disease. Biologic therapy medications are proteins that are given by injection or infusion and suppress the inflammation process by blocking the action of cytokines, which are proteins that promote systemic inflammation. Previous research has shown a clear link between psoriasis and the development of high-risk coronary plaque.
This study provides a characterisation of a lipid-rich necrotic core, a dangerous type of coronary plaque made up of dead cells and cell debris that is prone to rupture. Study Confirms Elucid’s AI Software Accurately Estimates Lesion-Specific Ischemia Compared to Standard of Care. BOSTON – February 18, 2020 –Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced today the publication of new clinical data in the International Journal of Cardiology.
The study, entitled “Coronary plaque assessment of Vasodilative capacity by CT angiography effectively estimates fractional flow reserve”demonstrates that Fractional Flow Reserve (FFR) assessment derived from non-invasive plaque morphology using Elucid’s software is highly accurate as compared to invasive FFR.
The team at Medical University of South Carolina (MUSC), led by Akos Varga-Szemes, MD and Joseph Schoepf, MD showed that Elucid’s AI software can quantitate both vessel structure and histologically-validated plaque composition from a routine CT angiography (CTA). These measurements were fed into Elucid’s computational neural networks to accurately estimate ischemia. Elucid Bioimaging Medical Technology Company (Health & Beauty - Fitness) Elucid.
Elucid Bioimaging Medical Technology Company (Health & Beauty - Fitness) Elucid Bioimaging Medical Technology Company (Health & Beauty - Fitness) Products & Services. VascuCAP Clinical Edition atherosclerotic plaque evaluation. Atherosclerotic Plaque Quantiation.